Immutep (ASX:IMM) said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.

IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with "significant," long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.

The firm's shares fell past 1% in recent trading on Monday.